🚨 #ESMO26 | PANKU-Breast01 🇨🇳

Izalontamab brengitecan (iza-bren), an EGFR×HER3 bispecific ADC, significantly improved PFS 🆚 physician’s choice chemotherapy in HR+/HER2− advanced #BreastCancer after endocrine therapy, CDK4/6i and 1–2 chemotherapy lines.

🔹 mPFS: 8.2 🆚 4.0 months (HR 0.41)
🔹 Confirmed ORR: 40.5% 🆚 20.2%
🔹 OS remains immature

⚠️ Grade ≥3 TRAEs: 85% 🆚 66%, predominantly haematological.

🎯 Promising efficacy in a heavily pretreated population; toxicity and validation beyond China remain key considerations.

📖 Simultaneously published in @TheLancet : http://thelancet.com/journals/lancet/S0140-6736(26)02096-9?dgcid=twitter_organic_clinical_esmo26_red_lancet

@OncoAlert @myESMO